Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
复制标题
DOI：
10.1177/0269881112460109
复制
发表时间：
2013-01-01
影响因子：
4.1
通讯作者：
Kapur, Shitij
中科院分区：
文献类型：
--
作者：
Englund, Amir;Morrison, Paul D.;Kapur, Shitij
基于社区的研究表明，含有高达9-四氢大麻酚(THC)但低大麻二酚(CBD)的大麻产品对精神健康尤其有害。基于实验室的研究是澄清这一问题的理想选择，因为THC和CBD可以在受控条件下以纯形式给药。在受试者之间的设计中，我们测试了CBD预治疗抑制THC诱发的精神病和认知障碍的假设。健康参与者随机接受口服CBD 600 mg(n=22)或安慰剂(n=26)，提前210分钟静脉注射THC(1.5 mg)。术后，CBD组PANSS阳性评分较低，但差异无统计学意义。然而，与安慰剂组相比，CBD组临床显著的阳性精神病症状(先验定义为增加3分)的可能性较小，优势比(OR)=0.22(X2=4.74，p<；0.05)。一致认为，与安慰剂组相比，CBD组的社会偏执狂(SSPS)评分低于安慰剂组(t=2.28，p<；0.05)。情节记忆，以霍普金斯语言学习任务-修订版(HVLT-R)的分数为指标，相对于基线，安慰剂预治疗组(-10.6+/-18.9%)比CBD组(-0.4%+/-9.7%)差(t=2.39，p<；0.05)。这些发现支持这样一种观点，即高THC/低CBD大麻产品与精神健康风险增加有关。
Community-based studies suggest that cannabis products that are high in Delta 9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were randomised to receive oral CBD 600mg (n=22) or placebo (n=26), 210 min ahead of intravenous (IV) THC (1.5 mg). Post-THC, there were lower PANSS positive scores in the CBD group, but this did not reach statistical significance. However, clinically significant positive psychotic symptoms (defined a priori as increases ayen3 points) were less likely in the CBD group compared with the placebo group, odds ratio (OR)=0.22 (chi 2=4.74, p < 0.05). In agreement, post-THC paranoia, as rated with the State Social Paranoia Scale (SSPS), was less in the CBD group compared with the placebo group (t=2.28, p < 0.05). Episodic memory, indexed by scores on the Hopkins Verbal Learning Task-revised (HVLT-R), was poorer, relative to baseline, in the placebo pre-treated group (-10.6 +/- 18.9%) compared with the CBD group (-0.4%+/- 9.7 %) (t=2.39, p < 0.05). These findings support the idea that high-THC/low-CBD cannabis products are associated with increased risks for mental health.